Biovet JSC (LTS:0III) Research & Development: лв3.36 Mil (TTM As of Dec. 2016)


What is Biovet JSC Research & Development?

Biovet JSC LTS:0III Research & Development is лв3.36 Mil as of Dec. 2016. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Biovet JSC's Research & Development for the three months ended in Dec. 2016 was лв0.84 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2016 was лв3.36 Mil.

Biovet JSC  (LTS:0III) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Biovet JSC Research & Development Related Terms

Biovet JSC Research & Development Historical Data

* Premium members only.

The historical data trend for Biovet JSC's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biovet JSC Research & Development Chart

Biovet JSC Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Research & Development
Get a 7-Day Free Trial 3.56 2.69 2.89 3.52 3.36

Biovet JSC Quarterly Data
Dec09 Dec10 Dec11 Dec12 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.82 0.93 0.78 0.84

Biovet JSC Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was лв3.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of лв3.36 Mil mean?
Biovet JSC (LTS:0III) has a Research & Development of лв3.36 Mil as of Dec. 2016. Research and development expense is the total cost for research and development activities. View historical data on Biovet JSC and its competitors.
Is Biovet JSC's Research & Development too high?
Biovet JSC's current Research & Development is лв3.36 Mil.
How does Biovet JSC's Research & Development compare to ADMP and AGRX?
Biovet JSC's Research & Development of лв3.36 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Biovet JSC and its competitors. Biovet JSC's current Research & Development is лв3.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current Research & Development of лв3.36 Mil. The current Research & Development is лв3.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current Research & Development is лв3.36 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biovet JSC Business Description

Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.